ACLARIS THERAPEUTICS INC

ACRIS Therapeutics stock edges up 0.52 % despite sector sell‑off, showing a cautious rebound amid market volatility and a strong specialty‑drug pipeline.

Read how Aclaris Therapeutics (ACRS) edged up 1% despite a 33% monthly decline, its market cap, 200‑day average, and what analysts say about its future.

Explore Aclaris Therapeutics’ sharp rally to $3.81, a rebound from 32% lows, driven by strong pipeline news and near‑term upside expectations.

Aclaris Therapeutics shares climb 6.1% on Oct 20, trading at $3.76 with a $482.8M market cap, amid sector shifts and pipeline updates that boost investor confidence.